Axicabtagene ciloleucel

Generic Name
Axicabtagene ciloleucel
Brand Names
Yescarta
Drug Type
Biotech
Chemical Formula
-
CAS Number
-
Unique Ingredient Identifier
U2I8T43Y7R
Background

Axicabtagene ciloleucel is an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. The drug has a unique mechanism of action, as it utilizes the patient's own T cells, which play a central role in immune response to cancer. Once T-cells are collected from the patient, they are genetically engineered to express anti-CD19 CARs that recognize and kill canc...

Indication

In the US, axicabtagene ciloleucel is indicated for the treatment of adults with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy.
...

Associated Conditions
Refractory Diffuse Large B Cell Lymphoma (DLBCL), Refractory Follicular Lymphoma, Refractory Large B-cell Lymphoma, Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Relapsed Diffuse Large B-cell Lymphoma (DLBCL), Relapsed Follicular Lymphoma, Refractory High Grade B-cell Lymphoma (HGBCL), Relapsed High Grade B-cell Lymphoma (HGBCL), Relapsed Primary Mediastinal Large B-Cell Lymphoma (PMBCL)
Associated Therapies
-
Clinical Trials
Related News

Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy

First Posted Date
2021-10-13
Last Posted Date
2024-02-22
Lead Sponsor
NeoImmuneTech
Target Recruit Count
57
Registration Number
NCT05075603
Locations
🇺🇸

Duke Cancer Institute, Durham, North Carolina, United States

🇺🇸

City of Hope, Duarte, California, United States

🇺🇸

Barbara Ann Karmanos Cancer Hospital dba Karmanos Cancer Center, Detroit, Michigan, United States

and more 1 locations

Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells

First Posted Date
2021-09-13
Last Posted Date
2024-10-09
Lead Sponsor
Kite, A Gilead Company
Target Recruit Count
700
Registration Number
NCT05041309
Locations
🇯🇵

Kyoto University Hospital, Kyoto, Japan

🇯🇵

Okayama University Hospital, Okayama, Japan

🇺🇸

Children's Hospital Los Angeles, Los Angeles, California, United States

and more 66 locations

Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B Lymphoma Ineligible to Autologous Stem Cell Transplantation

First Posted Date
2020-08-28
Last Posted Date
2024-10-09
Lead Sponsor
The Lymphoma Academic Research Organisation
Target Recruit Count
62
Registration Number
NCT04531046
Locations
🇫🇷

Hôpital Saint Antoine, Paris, France

🇫🇷

Centre Hospitalier Lyon Sud, Pierre Bénite, France

🇫🇷

IUCT Oncopole, Toulouse, France

and more 13 locations

Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma

First Posted Date
2020-02-06
Last Posted Date
2024-10-29
Lead Sponsor
University of Washington
Target Recruit Count
50
Registration Number
NCT04257578
Locations
🇺🇸

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients with Recurrent or Refractory Large B-cell Lymphoma

First Posted Date
2019-12-20
Last Posted Date
2024-12-13
Lead Sponsor
Jonsson Comprehensive Cancer Center
Target Recruit Count
36
Registration Number
NCT04205838
Locations
🇺🇸

UC Davis Comprehensive Cancer Center, Davis, California, United States

🇺🇸

UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity

First Posted Date
2019-11-05
Last Posted Date
2024-12-19
Lead Sponsor
Marcela V. Maus, M.D.,Ph.D.
Target Recruit Count
15
Registration Number
NCT04150913
Locations
🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

🇺🇸

Dana Farber Cancer Institute, Boston, Massachusetts, United States

Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell Lymphoma

First Posted Date
2018-12-03
Last Posted Date
2024-12-04
Lead Sponsor
Kite, A Gilead Company
Target Recruit Count
42
Registration Number
NCT03761056
Locations
🇺🇸

Banner Health MD Anderson Cancer Center, Gilbert, Arizona, United States

🇺🇸

The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

🇫🇷

Hopital Saint Louis, Paris, France

and more 4 locations

Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma

First Posted Date
2018-01-05
Last Posted Date
2024-03-07
Lead Sponsor
Kite, A Gilead Company
Target Recruit Count
359
Registration Number
NCT03391466
Locations
🇺🇸

University of Chicago Medical Center, Chicago, Illinois, United States

🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

🇺🇸

The University of Texas, MD Anderson Cancer Center, Houston, Texas, United States

and more 69 locations

Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 1 and Cohort 2)

First Posted Date
2015-11-10
Last Posted Date
2024-02-12
Lead Sponsor
Kite, A Gilead Company
Target Recruit Count
105
Registration Number
NCT02601313
Locations
🇺🇸

Loyola University Chicago, Maywood, Illinois, United States

🇺🇸

Ohio State University, Columbus, Ohio, United States

🇺🇸

Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

and more 29 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy